changes in muscle soreness, as indicated by the VAS values obtained for the control and treated arms of the
subjects in each group on each day of the study, are illustrated in Figure 2.
Soreness increased from negligible levels on day 1 to appreciable levels in both arms in all groups by day 2.
Most groups reported peak levels of soreness on day 3, reaching levels that ranged between 29% and 45% of
the maximum possible rating (150 mm). Soreness began to decline toward baseline values by day 4 of the study.